The Global IgA Nephropathy Industry is on an upward trajectory, fueled by a projected Compound Annual Growth Rate (CAGR) of a remarkable 7.5% between 2023 and 2033. According to Future Market Insights (FMI), this significant growth surge is expected to propel the market valuation to a staggering US$85 billion by 2033.
This positive prognosis is supported by several important variables found in the thorough research that FMI carried out. It is expected that the increased incidence of renal disorders, together with an increase in R&D efforts, rising market participant investments, and ongoing technical advancements, would propel the market’s strong expansion.
One of the pivotal factors contributing to the projected market expansion is the growing number of initiatives taken by governments globally. Various governmental efforts aimed at providing facilities, such as reimbursement for diagnostic tests, are expected to play a significant role in boosting the Global IgA Nephropathy Industry.
Request for a sample Copy:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16217
The COVID-19 pandemic has been associated with an increase in hospitalization and infection hotspots around the country. There were at least three separate waves of COVID-19 around the world by June 2021 that put a significant strain on hospital resources, especially labor, and the availability of dialysis equipment & supplies. In addition, the COVID-19 pandemic has affected healthcare services for renal disease patients. Social distancing and lockdown were mandate norms, globally, leading to the temporary closure of other medical services. The diagnosis of several renal diseases was deferred during the pandemic due to the suspension of non-urgent visits and testing services.
On the other hand, increasing awareness regarding IgA nephropathy is expected to create lucrative opportunities for market growth. For instance, In the U.S., an estimated 37 million adults have kidney disease. Major risk factors for the disease are high blood pressure and diabetes as well as heart disease, obesity, & family history of kidney disease. In addition, North America and Asia Pacific are two major regions contributing to the IgA nephropathy market.
Key Takeaways from the Global IgA Nephropathy Industry Study
- IgA Nephropathy market to garner US$ 85 Billion by the end of 2033.
- IgA Nephropathy market to register a positive CAGR of 7.5% in the forecast period 2023-2033
- By end user, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
- By diagnosis, the urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years.
- North America is expected to possess 40% market share for IgA nephropathy market in 2023.
- Asia Pacific is expected to hold 35% market share for IgA nephropathy market share in 2023.
“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA nephropathy market” states a FMI analyst
Global IgA Nephropathy Industry Competitive Landscape
Some of the key companies in the IgA Nephropathy market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others
- In June 2021, Novartis Pharmaceuticals announced iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN).
- Chinook Therapeutics, Inc., a key player in the IgA nephropathy market is focusing on diagnosing the causes of the ailment and offering customized and specific treatments based on the same.
Buy This Report:
https://www.futuremarketinsights.com/checkout/16217
Key Segments Profiled in the Global IgA Nephropathy Industry Survey
Diagnosis:
- Iothalamate Clearance Test
- Kidney Biopsy
- Blood Tests
- Urine Tests
Diseases Type:
- Primary IgA Nephropathy
- Secondary IgA Nephropathy
Systems:
- Hematuria
- Proteinuria
- Edema
- Others
Population Type:
- Pediatrics
- Adults
Route of Administration:
- Oral
- Parenteral
- Others
Treatment:
- Medication
- Statin therapy
- Omega-3 fatty acids
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin receptor blockers (ARBs)
- Diuretics
- Immunosuppressants
- Kidney Transplantation
- Others
End Users:
- Hospitals
- Specialty Clinics
- Homecare
- Others
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
